NATICK, Mass. — Allurion Technologies, Inc. said it has filed an appeal with the New York Stock Exchange after the exchange moved to begin delisting proceedings against the company’s securities for failing to meet minimum market capitalization requirements.
The company said the NYSE initiated the proceedings under Section 802.01B of its Listed Company Manual, which requires listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30 trading day period.
Allurion said it has submitted a detailed plan to the NYSE aimed at regaining compliance with listing standards or relisting its securities on the NYSE American. The plan also includes strengthening the company’s balance sheet and funding commercialization of its recently approved Allurion Smart Capsule in the United States.
The company said its strategy was catalyzed by the U.S. Food and Drug Administration’s recent approval of the Allurion Gastric Balloon System, which features the Allurion Smart Capsule.
“We have been in regular contact with the NYSE about our step-by-step plan to regain compliance with its listing standards or initiate listing on the NYSE American,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “The first step in our plan was receiving FDA approval, which was received on February 20, 2026. We are leveraging this approval to touch off the remaining parts of our plan to ultimately regain compliance or relist.”
Gaur said the company expects the approval to support its efforts to expand in the U.S. obesity treatment market.
“We are confident we can execute this plan, setting up Allurion to capitalize on our U.S. FDA approval and enabling us to treat the more than 100 million Americans suffering from obesity, 20 million of whom have already tried a GLP-1 but discontinued use,” he added.
Allurion said its securities are currently trading on the OTCID exchange while the company works to execute its compliance plan and pursue relisting. The company noted that there is no assurance the appeal or its efforts to regain compliance will ultimately succeed.
